Concord is a healthcare private equity firm established in October 2017 under the laws of the State of Delaware as a Limited Liability Company. Headquartered in Summit, New Jersey, the firm is led by James T. Olsen (“Mr. Olsen”) who is the principal owner of Concord and controls the policies of Concord. Mr. Olsen has over 25 years of experience in healthcare private equity and investment banking and serves as the Managing Partner of Concord. Concord serves as an investment manager and provides investment advisory services to private investment partnerships. Currently, this includes AHA Innovation Development Fund, L.P. (“Fund I”) and Concord Innovation Fund II, L.P. (“Fund II”), both Delaware limited partnerships as well as CHP Cedar SPV, LLC (“Cedar SPV”) and CHP Cedar SPV II, LLC (“Cedar SPV II”), both Delaware limited liability companies (hereinafter each a “Fund” and collectively the “Funds”). The Funds make primarily significant minority investments in growth stage healthcare companies. Concord’s investment strategy primarily focuses on healthcare information technology, healthcare services, healthcare tech-enabled services and medical technology. Within these sectors, the Funds generally target companies that offer innovative technologies, solutions and/or services that are operational and/or strategically important to health providers and health insurers. Concord invests in companies with innovative technologies that lower the cost of care, improve quality and expand access to care. For further information about Concord’s investment strategy, including a description of how Concord seeks to transform the Funds’ portfolio companies, see “Methods of Analysis, Investment Strategies and Risk of Loss” below. Concord VC GP, L.P., a Delaware limited partnership, serves as the general partner of Fund I. Concord GP II, L.P., a Delaware limited partnership, serves as the general partner of Fund II, while

CHP Cedar SPV SM, L.P. serves as the special member to Cedar SPV and Cedar SPV II. This brochure describes the business practices of the general partners of Fund I and Fund II and the special member of Cedar SPV and Cedar SPV II, which operate as a single business together with Concord. Each general partner is subject to the Advisers Act pursuant to Concord’s registration in accordance with SEC guidance. For further information regarding these entities, see “Other Financial Industry Activities and Affiliations” below. As of the date of this filing, Concord has regulatory assets under management of $262,429,211 which it manages on a discretionary basis. In providing services to the Funds, Concord executes the investment objective for each Fund, directs and manages the investment of each Fund’s assets, and provides periodic reports to investors in each Fund. Investment advice is provided directly to each Fund and not individually to the Funds’ investors. Concord manages the assets of each Fund in accordance with the terms of the governing documents applicable to each Fund (the “Governing Documents”), which are generally established at the time of the formation of a Fund. The Fund investors may not direct investments by the Funds, and except in limited circumstances, investors are not permitted to withdraw from a Fund prior to completion of the Funds’ winding up. Investor interests in the Funds are not registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and the Funds are not registered under the Investment Company Act of 1940, as amended (the “Investment Company Act”). Accordingly, interests in the Funds are offered and sold exclusively to investors satisfying the applicable eligibility and suitability requirements either in private transactions within the United States or in offshore jurisdictions.